Eric is a chemist by training. He is currently heading the Medicinal Chemistry Group of Evotec ID Lyon while being the Evotec Innovate AMR portfolio leader. He worked for Sanofi and its predecessor companies (Rhône-Poulenc and Aventis) for almost 30 years before joining Evotec mid-2018. Eric has been working in the field of infectious diseases (antibacterial, anti-mycobacterials, anti-virals and anti-fungals) for more than 20 years. In the field of antibacterials, he has conducted or contributed to multiple research and preclinical development projects across numerous antibacterial targets and chemical series. This work led for instance to the clinical antibacterial candidates NXL-101 and NXL-103. Eric is particularly committed to the fight against AMR and, along these lines, he has contributed in recent years, as EFPIA co-coordinator of the IMI ENABLE consortium and as Project Lead for the GNA NOW consortium, to various European initiatives aiming at developing new classes of antibacterials active on the key drug-resistant Gram-negative pathogens.